Since the first FDA approval of anti-CTLA-4 (Ipilimumab) in 2011 [3], cancer immunotherapies have rapidly evolved, with more than half a dozen ICIs approved and numerous combination regimens under clinical evaluation [4, 5]. The gene discussed is CTLA4; the disease is cancer.